Income Statement Guardant Health, Inc.
Equities
GH
US40131M1099
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.49 USD | +1.75% |
|
-6.26% | -16.30% |
| Mar. 11 | Guardant Health, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01:00 PM | |
| Mar. 11 | Braidwell, Karnal and Kreiter's AI healthcare fund, surged 28% last year | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 374M | 450M | 564M | 739M | 982M | |||||
Total Revenues | 374M | 450M | 564M | 739M | 982M | |||||
Cost of Goods Sold, Total | 123M | 156M | 227M | 290M | 349M | |||||
Gross Profit | 251M | 293M | 337M | 449M | 633M | |||||
Selling General & Admin Expenses, Total | 399M | 464M | 451M | 545M | 705M | |||||
R&D Expenses | 263M | 374M | 365M | 348M | 364M | |||||
Other Operating Expenses, Total | 662M | 838M | 816M | 893M | 1.07B | |||||
Operating Income | -411M | -544M | -479M | -444M | -436M | |||||
Interest Expense, Total | -2.58M | -2.58M | -2.58M | -2.58M | -3.9M | |||||
Interest And Investment Income | 3.93M | 6.07M | 35.36M | 53.69M | 34.1M | |||||
Net Interest Expenses | 1.35M | 3.49M | 32.79M | 51.11M | 30.2M | |||||
Currency Exchange Gains (Loss) | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | 178K | -99.47M | 2.52M | 1.8M | 8.09M | |||||
EBT, Excl. Unusual Items | -409M | -640M | -444M | -391M | -398M | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | -13.09M | 50.66M | -44.4M | -18.58M | |||||
Legal Settlements | - | - | -83.4M | - | - | |||||
Other Unusual Items | 25M | - | -2.1M | - | -950K | |||||
EBT, Incl. Unusual Items | -384M | -653M | -479M | -435M | -418M | |||||
Income Tax Expense | 300K | 1.14M | 685K | 1.28M | -1.26M | |||||
Earnings From Continuing Operations | -385M | -655M | -479M | -436M | -416M | |||||
Net Income to Company | -385M | -655M | -479M | -436M | -416M | |||||
Minority Interest | -20.9M | - | - | - | - | |||||
Net Income - (IS) | -406M | -655M | -479M | -436M | -416M | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | -406M | -655M | -479M | -436M | -416M | |||||
Net Income to Common Excl. Extra Items | -406M | -655M | -479M | -436M | -416M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -4 | -6.41 | -4.28 | -3.56 | -3.32 | |||||
Basic EPS - Continuing Operations | -4 | -6.41 | -4.28 | -3.56 | -3.32 | |||||
Basic Weighted Average Shares Outstanding | 101M | 102M | 112M | 123M | 125M | |||||
Net EPS - Diluted | -4 | -6.41 | -4.28 | -3.56 | -3.32 | |||||
Diluted EPS - Continuing Operations | -4 | -6.41 | -4.28 | -3.56 | -3.32 | |||||
Diluted Weighted Average Shares Outstanding | 101M | 102M | 112M | 123M | 125M | |||||
Normalized Basic EPS | -2.73 | -3.92 | -2.48 | -1.99 | -1.98 | |||||
Normalized Diluted EPS | -2.73 | -3.92 | -2.48 | -1.99 | -1.98 | |||||
Supplemental Items | ||||||||||
EBITDA | -389M | -508M | -436M | -401M | -397M | |||||
EBITA | -409M | -542M | -477M | -441M | -435M | |||||
EBIT | -411M | -544M | -479M | -444M | -436M | |||||
EBITDAR | -364M | -480M | -407M | -370M | -363M | |||||
Total Revenues (As Reported) | 374M | 450M | 564M | 739M | - | |||||
Effective Tax Rate - (Ratio) | -0.08 | -0.17 | -0.14 | -0.3 | 0.3 | |||||
Current Domestic Taxes | 4K | 127K | 35K | 126K | 90K | |||||
Current Foreign Taxes | 118K | 1.25M | 1.19M | 871K | 352K | |||||
Total Current Taxes | 122K | 1.38M | 1.23M | 997K | 442K | |||||
Deferred Domestic Taxes | 128K | 21K | - | - | - | |||||
Deferred Foreign Taxes | 50K | -257K | -541K | 287K | -1.7M | |||||
Total Deferred Taxes | 178K | -236K | -541K | 287K | -1.7M | |||||
Normalized Net Income | -277M | -400M | -277M | -244M | -249M | |||||
Interest on Long-Term Debt | 2.58M | 2.58M | 2.58M | 2.58M | 3.9M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 2.4M | 8.9M | 2.1M | - | - | |||||
Selling and Marketing Expenses | 192M | 300M | 295M | 365M | 495M | |||||
General and Administrative Expenses | 207M | 164M | 156M | 180M | 210M | |||||
Research And Development Expense From Footnotes | 263M | 374M | 367M | 348M | 364M | |||||
Net Rental Expense, Total | 24.7M | 28.6M | 29.7M | 31.1M | 33.6M | |||||
Imputed Operating Lease Interest Expense | 457K | 430K | 450K | 477K | 688K | |||||
Imputed Operating Lease Depreciation | 24.24M | 28.17M | 29.25M | 30.62M | 32.91M | |||||
Stock-Based Comp., COGS (Total) | 3.47M | 5.5M | 6.46M | 9.36M | 10.7M | |||||
Stock-Based Comp., R&D Exp. (Total) | 18.91M | 26.63M | 34.68M | 50.57M | 50.94M | |||||
Stock-Based Comp., S&M Exp. (Total) | 15.48M | 25.44M | 24.76M | 36.48M | 44.72M | |||||
Stock-Based Comp., G&A Exp. (Total) | 114M | 37.12M | 24.85M | 44M | 59.86M | |||||
Total Stock-Based Compensation | 151M | 94.68M | 90.76M | 140M | 166M |
- Stock Market
- Equities
- GH Stock
- Financials Guardant Health, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















